An example of this is seen in the ongoing Phase II Trial of anti-PD-L1 Atezolizumab + Bevacizumab in unresectable or metastatic melanoma (NCT04356729) for which long-term outcomes are not yet available. This evidence concerns the gene CD274 and metastatic melanoma.